Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2021 | MRD for multiple myeloma: is it ready for prime-time?

Philippe Moreau • 10 Sep 2021
IMW 2021
Multiple Myeloma

Philippe Moreau, MD, Nantes University Hospital, Nantes, France, talks on the use of measurable residual disease (MRD) to drive adaptive therapy in multiple myeloma. Prof. Moreau explains the issues surrounding the use of MRD, such as cost and time consumption. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

More from Philippe Moreau

Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma 1:15
Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau • 15 Feb 2023
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy 4:49
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy
Philippe Moreau • 15 Feb 2023
Optimal treatment strategies for multiple myeloma 3:02
Optimal treatment strategies for multiple myeloma
Philippe Moreau • 10 Sep 2021
Optimal treatment sequencing for relapsed/refractory myeloma 1:59
Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau • 10 Sep 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals